Small Molecules

Research suggests diabetes patients using SGLT-2 and DPP-4 inhibitors have a decreased risk of developing dementia.

What’s going on with nitrosamines? Naiffer Romero from the USP walks us through frequently asked questions.

Civica Rx is approaching generic drug manufacturing using a nonprofit model – and it’s working. We get the story behind their facility in Petersburg.

Drug shortages are everywhere. We speak with Vimala Raghavendran at the US Pharmacopeia to get the full picture.

Who deserves a place on our annual list of inspirational and influential industry professionals?

Tips to identify a safe, cost-efficient, and sustainable route to scalable API synthesis

The use of AI in small molecules drug discovery is driving the sector in big ways – but there are big challenges too. Here are five steps to success

The repurposing of legacy small molecules drugs could be more advantageous than previously known. Case in point: Arsenic

Patient needs are changing, but small molecule drugs remain as important as ever. Here are some tips for development success.

Could J&J’s combination treatment for PAH bridge the gaps between guidelines and practice, while easing the burden on patients?